Industrial and academic research teams work together on the project Mondriaan in order to develop an infrastructure for coupling existing pharmaceutical, medical/clinical and care data in the Netherlands. The aim is to make data available for scientific research in the field of effectiveness and safety of medicines.

InnoTact identified the potential interested parties for the future infrastructure. We presented the achieved and intended project results in order to explore their interest in the formation of the infrastructure.

The conclusion was that the Mondriaan initiative could create a position for itself within the landscape of health research in the Netherlands. The aim was to achieve clear-cut demarcation and transparent products, in combination with defining markets. We developed these and evaluated them against the ideas of the project team.
We asked the ‘outside world’ about the added value of this type of design for Mondriaan. We also gained an insight into the potential forms of compensation to data suppliers, the scope of the market and the value of the datasets during this round of interviews.

We made recommendations in respect of the strategy and positioning for Mondriaan that will lead to a financially independent entity that can successfully participate in the business sector traffic after 2011. And the setup of the organisation and operations to support this.

During the remaining 2.5 to 3 years of the project, the responsible persons know which choices have to made and which action must be undertaken in order to facilitate the structural continuation of the Mondriaan initiative after 2012. This infrastructure for coupling the existing pharmaceutical, medical/clinical and care data is a strong contributory factor to the TI Pharma objective: to shorten the expensive ‘drug’ development process and simultaneously reduce the risks of ‘clinical failure’ of new medicines.

 Back to overview of the cases

Cases

• Developing business cases PSI
• Outlines LS Amsterdam Metropolitan Area
• International benchmark of bio-clusters
• Life Sciences sector in India
• Expertise centre Environmental Toxicology
• Interim evaluation IOP Genomics
• Carbohydrate Competence Center
• Industrial bio-processing in the north of the Netherlands
• Business case TI Pharma Mondriaan project
• Life Sciences sector in the Netherlands
• Technology platform microbial detection
• Evaluation BioPartner programme
• National technology platform drug discovery
• Strategy Cilian, German LS company
• Business plan spin off Unilever
• SME - Technology scan

Related Case(s)

• Developing business cases PSI
• Business plan spin off Unilever